Introduction
Doxorubicin is a medication employed in treatment regimens of the ever-growing epidemic of cancer. Antineoplastic drugs used for chemotherapy are renowned for their extensive side-effect profile, which ranges from unpleasant to fatal, and doxorubicin is no exception. Doxorubicin's mechanism of action involves inhibition of the synthesis of and damage to DNA, and formation of reactive oxygen species (ROS) to create oxidative stress in the cellular environment. These effects are not limited to tumour cells; healthy cells are also affected, including stem cells. As they are responsible for the growth and repair of a wide range of tissues in the body, damage to stem cells has the potential to cause lifelong health problems for a patient treated with doxorubicin. This review discusses the potential ways doxorubicin can influence cells, the current observed effects of chemotherapy on stem cells, particularly mesenchymal stem cells (MSCs) , and what is already known about doxorubicin's effects on stem cells, but which has not been reviewed in this manner to date. Caesius bacteria. [1] The anthracycline backbone is comprised of a tetracyclic aglycone ring with adjacent quinonehydroquinone groups and an attached daunosamine sugar. [1, 2] Doxorubicin is distinguished from other anthracyclines by the addition of a methoxy group to the tetracyclic ring system, and methyl groups to the C-9 side chain and daunosamine sugar. [2] Anthracyclines, including doxorubicin, exert their action via multiple mechanisms. These biological effects do not discriminate between cells of cancers and healthy cells and are discussed in turn below.
Class of drug, chemical structure and mechanism of action

Inhibition of DNA synthesis
It has been shown that doxorubicin is able to intercalate deoxyribonucleic acid (DNA) via the insertion of doxorubicin as a planar chromophore between the planar DNA base pairs, binding to them via hydrogen bonds. [3] The drug's hydroxyl and sugar amino groups are responsible for these covalent interactions. [4, 5] Intercalation of DNA results in double-stranded DNA breakage and gives rise to apoptosis. [3, 4] Doxorubicin has also been shown to lead to the inhibition of DNA and RNA polymerase enzymes, though it was found to have a higher preference for DNA polymerase. [6] Blockage of these enzymes prevents a cell from undergoing normal DNA and RNA synthesis. [3, 6] It must be noted that outcomes of in-vivo studies on doxorubicin's DNA and RNA polymerase inhibition are inconclusivesome show that plasma concentrations above those used therapeutically (approximately 1-2 lM) are required for such effects, while others display enzyme inhibition at these levels. It has been proposed that enzyme inhibition is only a cytostatic (rather than cytotoxic) and transient component of drug action. [3] Interference of topoisomerase II activity Topoisomerase II is an enzyme that regulates DNA topology (the pattern by which two complementary strands are intertwined) via creating temporary cuts in both strands of DNA during replication. This relaxes the DNA and prevents both negative and positive superhelical twists, knots and nucleic acid tangles. [7, 8] Doxorubicin takes advantage of topoisomerase II by stabilising the enzyme-DNA intermediate complex that is responsible for the cleavage, resulting in higher concentrations of the complex within the cell. Thus, more than the standard number of doublestranded DNA cuts are formed and rather than being transient, much of the damage becomes permanent. [8] Cell death then occurs as fragmented DNA cannot be transcribed, and the cell is unable to undergo normal mitotic processes.
Free radical damage to cells
Doxorubicin is able to accept an electron at its quinone groups, forming a semiquinone in the presence of enzymes NADH dehydrogenase, xanthine oxidase and cytochrome P450 reductase. This semiquinone can damage DNA itself as well as return to its parent quinone by reducing oxygen, forming ROS such as hydrogen peroxide and superoxide. [3, 9, 10] Under normal conditions tissues can tolerate the presence of ROS. However, when levels exceed the capacity of intrinsic antioxidant defences, cellular damage occurs. This includes DNA strand scission and peroxidation of unsaturated fatty acids leading to cellular membrane damage. [3, 10] Doxorubicin is given via intravenous injection or infusion and typically displays a triphasic plasma clearance and a terminal half-life of 24-36 h. [11] Doxorubicin is used in multidrug regimens in the treatment of cancers including but not limited to solid tumours such as breast cancer, [1] ovarian cancer [12] and osteosarcoma [3] as well as haematopoietic malignancies such as lymphomas and leukaemia. [13] Stem cells: an overview Stem cells can be subdivided into two main groups: adult/ somatic and embryonic stem cells. [14] Embryonic stem cells (ESCs) are derived from the inner cell mass of a human blastocyst, which forms 3 to 5 days after an egg is fertilised. These cells are described as pluripotent because there is a possibility for them to develop into all three embryonic germ layers: endoderm (gut epithelium); ectoderm (neutral epithelium, embryonic ganglia and stratified squamous epithelium); and mesoderm (cartilage, bone, smooth muscle and striated muscle). [15] ESCs are shown to express high levels of telomerase, a ribonucleoprotein that is involved in maintaining telomere length. The expression of this protein is correlated with immortality in cell lines, allowing ESCs to have a long replicative lifespan and maintain the capacity to differentiate into the three germ layers in vitro. [15] Somatic stem cells are present in almost every tissue in an adult body and have a narrower differentiation potential than ESC, only being able to differentiate into several or a single type of cell. They are used for tissue maintenance and repair. [14] The bone marrow is a large source of somatic stem cells, including both subcategories: haematopoietic and mesenchymal. [14] MSCs are able to differentiate into osteoblasts (bone), adipocytes (fat), chondrocytes (cartilage) and myoblasts (muscle); [14] haematopoietic stem cells can form every type of blood cell, such as erythrocytes and platelets. [16] Mesenchymal stem cells When isolated, MSCs are normally derived from bone marrow, however are also present in umbilical cord blood, salivary glands, adipose tissue and other organs including the gut. [17, 18] The International Society for Cellular Therapy states that in order for a cell to be classed as MSC, it must (1) possess certain surface markers such as CD105, CD70 and CD90 and lack expression of others including CD45, CD34, CD14 or CD11b, (2) must be plastic-adherent when maintained in standard culture conditions and (3) must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. [19] The differentiation of MSCs firstly involves commitment to a lineage-specific progenitor and then maturation from progenitors to a specific cell type. [20] Lineage commitment is under the control of several critical signalling pathways, including wingless-type MMTV integration site (Wnt), Hedgehog, Notch, transforming growth factorb (TGFb) and bone morphogenetic protein (BMP), and fibroblast growth factors. It has also been proposed that the nature of the cell's microenvironment has some control over its fate, with the phenotype formed being determined by the level of surrounding tissue elasticity. For example, MSCs in rigid matrices that resemble bone give rise to osteogenic progenitors; softer matrices mimicking brain give neurogenic cells. [21] More recently, differentiation has been found to be under the influence of microRNAs, molecules that control post-translational gene expression. [20, 22] By targeting transcription factors, microRNAs can up-or downregulate the differentiation of different cell lineages. [22] 
Patterns of differentiation
In-vitro studies have proposed a hierarchal model of differentiation, with the early MSCs undergoing a sequential loss of lineage potential as they differentiate down the proposed levels; first adipogenic is lost, then chondrogenic. Following this, the residual cells were found to be primarily osteogenic, suggesting that the osteogenic pathway is the 'default' outcome remaining if a cell is not committed to another phenotype. [23, 24] Formation of mature osteocytes is a multistep process. Firstly, the cells differentiate into preosteoblasts under the direction of multiple signalling pathways and transcription factors such as RUNX2. [25] Secondly, TGFb induces the migration of pre-osteoblasts to sites of bone resorption, [26] the microenvironment of which is stiff and elastic (thus favouring osteogenesis) and where mechanical factors promote a more flattened cell shape. [21, 27] Then, local soluble factors including BMP and insulin-like growth factors (IGFs) activate multiple signalling pathways which promote pre-osteoblast maturation into mineralised tissue. [28] Effects of chemotherapeutics on stem cells
Medication-induced elevation of ROS is one method of targeting cancer cells via causing damage to proteins, DNA and lipids. [29] Stem cells have mechanisms for DNA repair and oxidative stress defence. Compared to somatic cells, ESCs have been shown to have higher antioxidant enzyme levels, including superoxide dismutase and glutathione/ thioredoxin systems, and reduced accumulation of ROS, resulting in a better defence mechanism against oxidative stress.
[30] However, these features were lost upon differentiation. In-vitro studies [29, 31] found that higher levels of ROS were associated with suppression of MSC osteogenesis while favouring adipogenesis. Free radical generation adjacent to rodent bones in vivo is associated with formation of new osteoclasts and higher levels of bone resorption, not unlike the effects of signalling molecules such as parathyroid hormone (PTH) and interleukin-1 (IL-1). [32] PTH and IL-1 induce osteoclastic breakdown of bone to release minerals with the intention of raising the levels of free calcium, phosphate, magnesium and other minerals in the blood: tipping the balance in favour of resorption over ossification. Indeed, higher levels of oxidative stress have been associated with reduced bone mineral density and higher risks of osteoporosis. [33] Nicolay et al. studied the effects of bleomycin, an antineoplastic drug which forms free radicals and induces double-stranded DNA breaks, on MSCs. [34] It was found that following the administration of the drug, MCSs underwent an increased rate of apoptosis and while their adipogenic differentiation potential was reduced, chondrogenic differentiation was not affected. The cells were more sensitive to the drug than the lung fibroblasts they were compared with. However, there were no changes to cell morphology, surface marker expression and the ability to migrate and adhere. It was also found that the MSCs could repair the DNA breaks to some extent; thus, the main proposed mechanism of cell death was via free radical damage. [34] Prevention of mitosis is a mechanism of action expressed by drugs such as paclitaxel, etoposide, anthracyclines and cytarabine by means of inhibiting or enhancing the activity of certain enzymes such as topoisomerase II or arresting the mitotic cycle. In 1997, Carlo-Stella et al. studied the effects of acute myeloid leukaemia treatment protocols including such drugs (idarubicin, daunorubicin and etoposide) on the entire bone marrow environment and found that they left the marrow defective and unable to completely support haematopoietic progenitors and stromal cells. [35] This study did not include MSCs nor the mechanism of the damage. However, a later study (Li et al. [36] ) measured the effects of etoposide, cytarabine and paclitaxel on MSCs, and the results were consistent: reduction in proliferation, apoptosis and lack of recovery after 9 days (retention of lineage potential was not studied). These results are contradictory to Mueller et al., [37] who found that MSCs were indeed resistant to etoposide, retaining proliferation and lineage potential. Although these cells were treated for shorter amounts of time, the authors were able to isolate viable MSCs from the bone marrow of humans treated with chemotherapy. [37] Mueller et al. also compared the characteristics of MSCs isolated from the bone marrow of patients who had been exposed to standard-or highdose chemotherapy with those from unexposed bone marrow; no obvious differences in proliferation capacity and differentiation potential were found. [37] Interestingly, Li et al. [36] also found that MSCs suffered minimal damage and almost complete recovery after exposure to the alkylating agents cyclophosphamide and busulfan. The mechanism of action of these drugs involves irreversibly attaching an alkyl group to the DNA helix which causes strand breakage and replication inhibition. A case report of a human patient receiving cyclophosphamide treatment obtained similar outcomes. [38] MSCs have also shown resistance in vitro to treatment with drugs such as cisplatin, camptothecin and vincristine (alkylating agent, topoisomerase I inhibitor and mitotic inhibitor, respectively); full recovery and maintenance of lineage potential were observed. [36, 37, 39] Inconsistency in results suggests that resistance may be influenced by external factors, such as the composition of the cell culture medium or duration of treatment; further in-vivo studies are needed to form conclusions that can be extrapolated to humans.
The above findings suggest that the extent of damage to the MSCs and the bone marrow environment depends on the mechanism of action of the chemotherapy drug in question, whether it be DNA damage, mitosis inhibition, enzyme inhibition or free radical generation. There is a lack of data involving the long-term effects of chemotherapy on in-vivo MSCs and the bone marrow environment. Additionally, the precise mechanisms of resistance to chemotherapeutics have not been pinpointed and require further investigation; it has been suggested that the cells possess or have the ability to develop mechanisms for repairing DNA cuts and damage, that the in-vivo response to acute injury may involve cell migration, induction of differentiation and proliferation, and that the apoptotic threshold may be elevated. [34, 37, 40, 41] It has also been found that antioxidants were able to reduce the levels of apoptosis in MSCs. [36] 
Doxorubicin and stem cells
The complete range of influence doxorubicin has on MSCs has not yet been clearly elucidated. Due to its multiple and unique mechanisms of action, changes to MSC health, proliferation and lineage potential cannot be confidently predicted from studies on similar drugs. To make in-vivo data harder to obtain, doxorubicin is often used in combination therapy with drugs such as cyclophosphamide, methotrexate and corticosteroids, making it difficult to measure the effects of doxorubicin alone.
Negative effects of doxorubicin were reported on MSCs both in vitro and in vivo (murine) by Oliveira et al. [42] Responses in the cells included lower proliferation rates, alkaline phosphatase production deficiency, reduced potential for differentiation into cardiomyocytes and cytotoxicity via apoptosis; however, positive and negative cell surface markers remained the same as the control. The doxorubicin-exposed cells also did not express cardiac troponin T following cardiomyogenic differentiation induction, unlike the control group. This hints that the drug's influence on MSCs may be partially responsible for its cardiotoxic adverse effects. Similar cytotoxic responses to doxorubicin were obtained by Yang et al., [43] namely cell shrinkage, apoptosis and enhanced ROS production leading to mitochondrial membrane damage. It was also found that doxorubicin increased expression of mitogen-activated protein kinases (MAPK) signalling pathway precisely p38 and jun N-terminal kinase (JNK), which plays an important role in induction of inflammatory and apoptotic responses to oxidative stress, among others. [43, 44] When MAPK inhibitors were introduced into culture, lower levels of apoptosis were observed. Elevated levels of these factors have consistently been reported in other studies of doxorubicin-treated cells. [45, 46] Yang et al. [43] also reported that doxorubicin increased the expression of p53 and cleaved-caspase-3 proteins, which signalled downstream genes including B-cell lymphoma 2 (Bcl-2) and Bcl-2-like protein 4 (Bax) to cause cellular apoptosis. Thus, one hypothesised reason for apoptosis was via ROS activation of phosphorylated p38, p53 and JNK. [43, 47] In the same study, the secretion of vascular endothelial growth factor and insulin-like growth factor 1 (IGF-1) was decreased by doxorubicin. These factors are involved in the proliferation of and anabolic responses of types of cells [48] and angiogenesis. [49] While this is a desirable effect in reducing tumour size, it could decrease the ability of MSCs to heal and maintain adult tissues. [43, 47, 48] As MSCs have such a high regenerative potential, their presence and influence have been associated with promotion of tumour growth, such as apoptosis control, vascular support, suppression of immune response and modulation of response to cytotoxic therapy. [50, 51] MSCs appear to migrate to injured tissue sites which includes both solid tumours and the bone marrow in the case of haematological malignancies as such tissues often resemble those in need of repair. [52] MSCs can potentially promote tumour growth via stimulating angiogenesis in ischaemic tissue, [53] paracrine secretion of multiple anti-apoptotic factors and growth factors, and differentiating into carcinoma-associated fibroblasts which promote metastasis and drug resistance. [54, 55] Results are conflicting in experimental models. Chen and colleagues [56] reported triple negative breast cancer showing increased resistance to doxorubicin upon interaction with adipose-derived MSCs (ASCs). The mechanism of such results involved decreased intracellular doxorubicin accumulation within the breast cancer cells due to increased breast cancer resistance protein (BCRP) expression, and increased secretion of IL-8 cytokines. MSCs also appear able to aid breast cancer cells to evade immune system attack via increasing helper T cell (Th) Th1 and TGF-ß1 production. [57] Building upon these findings, a study by Karnoub et al. [58] showed that the combination of MCSs with weakly metastatic human breast carcinoma cells led to a significant increase in the cells' metastatic potential when the cells formed a xenograft. Increased secretion of the chemokine CCL5 from MSCs led to paracrine responses in the breast cancer cells, stimulating their motility and metastasis. A study by Tu et al. [59] showed osteosarcoma cells of the subtypes Saos-2 and U2-OS also displaying improved survival rates from both doxorubicin and cisplatin treatment when grown in a medium containing MSCs compared to control. Such cells displayed significantly lower levels of caspase 3/7 activity, thus preventing apoptosis, and higher activity of IL-6 and STAT3 (signal transducer and activator of transcription 3), mediators in osteosarcoma proliferation. Conclusive results were also obtained in vivo from mouse models. [59] Multiple studies have shown STAT3 inhibition being to be able to reverse drug (including doxorubicin) resistance, suggesting that STAT3 is important in resistance development. [59] [60] [61] Other experimental models present different outcomes. No significant changes in doxorubicin sensitivity were displayed by A459 lung cancer cells that had been treated in culture with Wharton's jelly-derived MSC secretome, the name given to the immunomodulatory cytokines, growth factors and chemokines produced by MSCs. [62] It is noted that only the isolated secretome was used; this suggests the secretome alone may not be responsible for resistance/sensitivity induction, or may be unable to produce such outcomes without presence of MSCs themselves. Ryu et al. [63] and Kucerova et al. [64] observed suppression of human breast cancer cell growth and increased chemosensitivity to doxorubicin, respectively, when in contact with ASCs. Causes of increased sensitivity were unclear. Similar growth inhibitory responses were expressed when human MSCs were intravenously injected into mice suffering Kaposi's Sarcoma; they migrated to tumour sites, and tumours decreased in size in a dose-dependent manner. [65] Bergfeld et al. [66] found that circulating bone marrow MSCs were incorporated into tumour cells and localised at the invasive front of tumours, enhancing their expansion and protecting them from drug-induced apoptosis. No definitive answer on the effects of MSCs on tumour growth in the presence of doxorubicin can yet be gleaned from the literature. It appears that the influence on drug resistance depends on a multitude of factors including the context of MSC presence and treatment, and the specific cell type, for example ASCs. The nature of the tumour also plays a part, whether the cells are actively dividing or dormant, the type of malignancy and surrounding stromal cells, and the cellular interactions within the tumour microenvironment. [64, 67] This raises the question of whether the cytotoxic effect of doxorubicin is indeed a negative thing; if MSCs aid tumour survival under exposure to treatment with drugs such as doxorubicin, toxic effects may not be so undesirable (Figure 1 ).
Doxorubicin has a wide range of adverse effects including immunosuppression, dyspigmentation, gastrointestinal disturbances leading to severe nausea and vomiting, and life-threatening cardiotoxicity. The latter typically presents as acute or insidious cardiomyopathy and heart failure and is exponentially dose-dependent. [68, 69] Anthracycline exposure to the cardiac progenitor cells or MSCs has been proposed as a cause for such toxicity, reducing the body's ability to heal and repair the heart. [43, 48] Current treatments include angiotensin-converting enzyme inhibitors, betablockers or heart transplantation. [70] The use of MSCs for cardio-protection or cardio-regenerative therapy in doxorubicin patients has been considered, however such therapy is undertaken with an air of caution due to the observed tumour-proliferation effects of MSCs in response to doxorubicin. [71] Several studies of such therapy have been successful and promising. Administration of bone marrow-derived MSCs (BMMSCs) 2 weeks after doxorubicin treatment generated significant improvement in left ventricular function in rabbits. [72] Another study in rats showed that daily dosing of BMMSCs for 10 days 10 weeks after doxorubicin treatment improved cardiac contractility and reduced myocardium fibrosis and left ventricular diameter. [73] Finally, contradictory to fears that MSCs may enhance tumour proliferation in the presence of doxorubicin, Oliveira et al. observed a partial cardioprotective effect in rats when treated with MSCs during doxorubicin therapy. [74] However, the duration of the beneficial effect is not known.
Conclusions
Due to the lack of long-term clinical studies on the consequences on stem cells of chemotherapy, projections of how doxorubicin may influence a patient's health posttreatment are not very clear. Stem cells are of vital importance in the maintenance and repair of human tissues. Certainly, the literature shows that drugs such as doxorubicin have the possibility to cause severe and possibly irreversible damage to the bone marrow environment and MSCs, via mechanisms such as free radical damage and induction of apoptotic pathways (summarised in Table 1 ). Whether this damage is clinically significant for the remainder of the patient's lifetime is not yet known. MSCs have been shown to lead to tumour resistance when under treatment with doxorubicin, this could affect the success of cancer treatment and the use of MSCs to repair tissues damaged by chemotherapy. Further investigation into the mechanisms of resistance to chemotherapy treatment could shed light on ways to overcome them.
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